Tracking the relative in vivo pharmacokinetics of nanoparticles with PARACEST MRI. - Wikidata - awgldk - TriplyDB

Tracking the relative in vivo pharmacokinetics of nanoparticles with PARACEST MRI.

Tracking the relative in vivo pharmacokinetics of nanoparticles with PARACEST MRI.

http://www.wikidata.org/entity/Q34437443

about

Advances in Magnetic Resonance Imaging Contrast Agents for Biomarker Detection Imaging in vivo extracellular pH with a single paramagnetic chemical exchange saturation transfer magnetic resonance imaging contrast agent Oxidation-Responsive, EuII/III-Based, Multimodal Contrast Agent for Magnetic Resonance and Photoacoustic Imaging In vivo imaging of paraCEST agents using frequency labeled exchange transfer MRI.The effect of regioisomerism on the coordination chemistry and CEST properties of lanthanide(III) NB-DOTA-tetraamide chelates.MRI stem cell tracking for therapy in experimental cerebral ischemia.Using two chemical exchange saturation transfer magnetic resonance imaging contrast agents for molecular imaging studies.A responsive europium(III) chelate that provides a direct readout of pH by MRI.In vivo detection of MRI-PARACEST agents in mouse brain tumors at 9.4 T.Chemical exchange saturation transfer (CEST): what is in a name and what isn't?Advantages of macromolecular to nanosized chemical-exchange saturation transfer agents for MRI applications.Non-invasive radiofrequency ablation of malignancies mediated by quantum dots, gold nanoparticles and carbon nanotubes.Quantification of water exchange kinetics for targeted PARACEST perfluorocarbon nanoparticles.An effective targeted nanoglobular manganese(II) chelate conjugate for magnetic resonance molecular imaging of tumor extracellular matrix Labile catalytic packaging of DNA/siRNA: control of gold nanoparticles "out" of DNA/siRNA complexes The pH sensitivity of -NH exchange in LnDOTA-tetraamide complexes varies with amide substituent pCEST: Positive contrast using Chemical Exchange Saturation Transfer Magnetic resonance chemical exchange saturation transfer imaging and nanotechnology.A catalyCEST MRI contrast agent that detects the enzyme-catalyzed creation of a covalent bond Biodistribution of small interfering RNA at the organ and cellular levels after lipid nanoparticle-mediated delivery Fluorescent and lanthanide labeling for ligand screens, assays, and imaging.Personalized nanomedicine advancements for stem cell tracking.A nano-sized PARACEST-fluorescence imaging contrast agent facilitates and validates in vivo CEST MRI detection of glioma.Measuring in vivo tumor pHe with CEST-FISP MRI Dendrimer-Based Responsive MRI Contrast Agents (G1-G4) for Biosensor Imaging of Redundant Deviation in Shifts (BIRDS).A reference agent model for DCE MRI can be used to quantify the relative vascular permeability of two MRI contrast agents.Detection of in vivo enzyme activity with CatalyCEST MRI.Targeting Triple Negative Breast Cancer with a Small-sized Paramagnetic Nanoparticle.The reciprocal linear QUEST analysis method facilitates the measurements of chemical exchange rates with CEST MRI.In vivo multicolor molecular MR imaging using diamagnetic chemical exchange saturation transfer liposomes.Nanoparticle-based theragnostics: Integrating diagnostic and therapeutic potentials in nanomedicine The hope and hype of multimodality imaging contrast agents.Two decades of dendrimers as versatile MRI agents: a tale with and without metals.Noninvasive detection of enzyme activity in tumor models of human ovarian cancer using catalyCEST MRI.ParaCEST Agents Encapsulated in Reverse Nano-Assembled Capsules (RACs): How Slow Molecular Tumbling Can Quench CEST Contrast.CEST and PARACEST Agents for Molecular Imaging Paramagnetic CEST MRI Contrast Agents

P2860

Q28830010-F99B7201-CCAE-4E4E-BC86-84E6FABE5B03 Q28833648-A8E97F62-17AC-4326-BE50-C534FA95F388 Q30359425-425B7215-1BD3-40B1-B75C-46EC27A4F4D9 Q30596967-F5D5902E-54DF-4D26-B94D-7D4FA9AB265E Q30703702-68BD06B1-3176-4B3E-B36D-4C7A27136B3E Q30712193-7655F488-E03D-4BB3-8DDD-DA88A2CFCCF6 Q33465177-0FB1C765-C847-4D23-9CD2-233BA67456BB Q33696320-B0EE5A84-798A-4D25-8F50-E7AA3847F439 Q33799575-C9FC6414-2C02-4CF2-A04C-21F5DBBB028E Q33825467-DB87D45F-9526-4B4B-8727-A81CF49F6422 Q33852464-789DC5BA-C255-4A1F-B037-F87AA65392CD Q33874638-55B8F887-0E70-44ED-9155-4F6D3DDA8847 Q33959557-1F05FF9D-B5FD-49AD-BA16-504C9DB1C991 Q34036970-92EE6A25-71CB-43AC-AD75-0800611E781D Q34058107-F9C56E5F-8BE9-4F30-8182-FDFC4BB84205 Q34092260-1DF0C3BE-9B42-423C-8386-97E4B1593670 Q34124666-818D7415-037E-4127-BD79-B5B922930639 Q34197669-2AE389FD-A8B2-41F2-B357-E91473D01562 Q34677812-F289F40E-40AE-48C5-A54B-790FD928E328 Q35681765-C0BA9842-A207-4373-9AAC-17AD451A2E4F Q36003339-C27FA54F-3C18-4A24-8367-A9ECF6098438 Q36335838-275DE716-3161-4FC5-9991-E05DAF32168F Q36478915-F83CFA2E-DFFA-4E22-9FC8-4D1305B6A2C3 Q36610934-E17A68CC-7320-439D-87B2-EF516D11650D Q36669347-386A075A-5AF0-44D7-8148-1CDBFA8744F9 Q37039971-C2E1718D-C3F5-484B-8F85-70C1A12A4880 Q37093095-3B5292C8-ABCE-4701-9720-341ACB943D31 Q37529757-B0395E74-97E9-4CBE-8187-EE8EA02EE8F6 Q38671052-0FC45507-D54B-4294-8700-30B465FBC78C Q39384901-9B35B304-A6F0-4D42-BAAD-EC980174AA78 Q42594981-9B46ACE4-97A2-42EE-9C34-3CEE4CD3B8D3 Q42697739-D3323BDA-02FC-46E0-A99E-1C7011C53E3D Q47686179-B27D91B6-EEAF-4298-A0B1-2D0467760695 Q48223655-48BB400E-63AA-4A6B-894B-8EAA9A97F2B8 Q52571069-1B0AE783-D26F-450B-B708-70913A9B7B8F Q58830272-9F1FD356-150C-4C88-8782-19A1F7CEFBBD Q58830282-72831FA5-B00F-4C13-A6B0-9EDF0E777074

P2860

Tracking the relative in vivo pharmacokinetics of nanoparticles with PARACEST MRI.

http://www.wikidata.org/entity/Q34437443

description

2009 nî lūn-bûn

@nan

2009 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Tracking the relative in vivo pharmacokinetics of nanoparticles with PARACEST MRI.

@ast

Tracking the relative in vivo pharmacokinetics of nanoparticles with PARACEST MRI.

@en

Tracking the relative in vivo pharmacokinetics of nanoparticles with PARACEST MRI.

@nl

type

label

Tracking the relative in vivo pharmacokinetics of nanoparticles with PARACEST MRI.

@ast

Tracking the relative in vivo pharmacokinetics of nanoparticles with PARACEST MRI.

@en

Tracking the relative in vivo pharmacokinetics of nanoparticles with PARACEST MRI.

@nl

prefLabel

Tracking the relative in vivo pharmacokinetics of nanoparticles with PARACEST MRI.

@ast

Tracking the relative in vivo pharmacokinetics of nanoparticles with PARACEST MRI.

@en

Tracking the relative in vivo pharmacokinetics of nanoparticles with PARACEST MRI.

@nl

P1433

Q34437443-B5EEF13F-1AD0-4601-A24F-6059C757FC4F

P1476

Q34437443-C8B53307-EF5F-44AB-9CBB-64F8ED98EB24

P2093

Q34437443-752BFE57-8002-4DB7-B9F4-882F70F47238

Q34437443-7910DD33-F14B-46DD-AF75-8E37619046C0

Q34437443-AC2071B6-F9AE-4C2B-AD3B-1AF1FB918DCC

P2860

Q34437443-02E24103-4FDA-4E03-9199-0D3C91A04699

Q34437443-147A09BF-FDEE-4322-AC4D-3DC54DB95E2D

Q34437443-32D9F77F-6DDA-4970-B09E-AFB5D95E03D8

Q34437443-4B6091C9-4AFB-453B-95A3-FC8482F4F027

Q34437443-4D7215EE-16B3-4238-BA25-B65CC3D18491

Q34437443-5AFC0969-942D-45DA-A8DD-A78B547953C4

Q34437443-5EA49714-0CE5-487B-99C9-B8075E18079A

Q34437443-789217A3-939D-424C-9C16-595FA5A8C107

Q34437443-7FE507EE-F77E-4839-8ABD-767212F2EC82

Q34437443-868860A4-B245-4370-8EDD-08A35995CE8D

P304

Q34437443-19480ECD-5B5C-4867-9BEB-88AA5A22A58C

P31

Q34437443-E9A69354-B7AE-4AAD-9044-39D0C926BE46

P356

Q34437443-CC1F4D5A-D44A-4873-98BC-709B29B5CF9D

P407

Q34437443-81BE8AA7-924E-4816-A0FB-B867472746AD

P433

Q34437443-E34F905B-02FA-4967-A0C2-46E5B13241E4

P478

Q34437443-CB10C23D-82D7-4E9F-97EA-F940B2E4A6C2

P577

Q34437443-1CD8360A-3FF2-42AB-A039-8AC5A00618A0

P698

Q34437443-AC7E6076-A0EF-4FB9-9CBA-F1A828B4AE82

P921

Q34437443-EE849DBF-4234-436F-8B4E-1A240C97AAF3

P932

Q34437443-198E4F54-6717-441B-BB55-516E114459F9

P356

P1433

Molecular Pharmaceutics

P1476

Tracking the relative in vivo pharmacokinetics of nanoparticles with PARACEST MRI.

@en

P2093

Byunghee Yoo

http://www.w3.org/2001/XMLSchema#string

M Meser Ali

http://www.w3.org/2001/XMLSchema#string

Mark D Pagel

http://www.w3.org/2001/XMLSchema#string

P2860

PARACEST MRI with improved temporal resolution

Magnetization transfer in MRI: a review.

Paramagnetic lanthanide(III) complexes as pH-sensitive chemical exchange saturation transfer (CEST) contrast agents for MRI applications.

Simultaneous measurement of arterial input function and tumor pharmacokinetics in mice by dynamic contrast enhanced imaging: effects of transcytolemmal water exchange.

Numerical solution of the Bloch equations provides insights into the optimum design of PARACEST agents for MRI.

Development and validation of a smoothing-splines-based correction method for improving the analysis of CEST-MR images.

A new class of contrast agents for MRI based on proton chemical exchange dependent saturation transfer (CEST).

Polymeric PARACEST agents for enhancing MRI contrast sensitivity.

Four-pool modeling of proton exchange processes in biological systems in the presence of MRI-paramagnetic chemical exchange saturation transfer (PARACEST) agents.

The amide protons of an ytterbium(III) dota tetraamide complex act as efficient antennae for transfer of magnetization to bulk water.

P304

1409-1416

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/MP900040U

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19298054

http://www.w3.org/2001/XMLSchema#string

P921

P932

4216567

http://www.w3.org/2001/XMLSchema#string